This document is a publication of a United States Patent and Trademark Office (USPTO) patent application, US20260079159A1, filed on September 12, 2025. The application, assigned to inventors Jeffrey A. Bluestone, Weihong Liu, and Amy Putnam, describes novel methods for isolating CD127lo/− immunosuppressive regulatory T cells, which are enriched for FoxP3 and possess suppressive function. These methods are intended for use in expanding the isolated cells, formulating pharmaceutical compositions, and treating autoimmune and other immune system-mediated disorders.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future developments in therapeutic approaches for immune disorders. Companies involved in pharmaceutical development, biotechnology, and cell therapy research, particularly those focused on autoimmune diseases or immunotherapy, should be aware of this filing as it may impact their intellectual property landscape and future research directions. No immediate actions are required by compliance officers, but monitoring patent filings in this area is advisable for strategic planning.